Studies have showed that reduced RKIP correlates with the chemoresistance of cervical cancer [16], lung adenocarcinoma [17], gastric cancer [18] and prostate and breast cancer [19], and upregulation of RKIP expression increases the sensitivity of cancer cells to chemotherapy [16–20]. This evidence concerns the gene PEBP1 and lung adenocarcinoma.